Search Legislation

The Health and Personal Social Services (General Medical Services Contracts)(Prescription of Drugs Etc) (Amendment) Regulations (Northern Ireland) 2011

What Version

 Help about what version
  • Latest available (Revised)
  • Original (As made)

Status:

This is the original version (as it was originally made). This item of legislation is currently only available in its original format.

Regulation 2

SCHEDULESCHEDULE 2 TO THE HEALTH AND PERSONAL SOCIAL SERVICES (GENERAL MEDICAL SERVICES CONTRACTS) (PRESCRIPTION OF DRUGS ETC) REGULATIONS (NORTHERN IRELAND 2004 AS SUBSTITUTED BY THESE REGULATIONS

This schedule has no associated Explanatory Memorandum

Regulation 3

SCHEDULE 2DRUGS, MEDICINES AND OTHER SUBSTANCES TO BE ORDERED ONLY IN CERTAIN CIRCUMSTANCES

Column 1

Drug

Column 2

Patient

Column 3

Condition

In this Schedule—

“at clinical risk” means in relation to a patient, a patient who—

(a)

has chronic respiratory disease;

(b)

has asthma that requires continuous or repeated use of inhaled or systemic steroids or with previous exacerbations requiring hospital admission;

(c)

has chronic heart disease;

(d)

has chronic renal failure;

(e)

has chronic liver disease;

(f)

has chronic neurological disease;

(g)

has diabetes; or

(h)

is immunosuppressed;

EEA Agreement” means the Agreement on the European Economic Area signed at Oporto on 2nd May 1992 as adjusted by the Protocol signed at Brussels on 17th March 1993;

“EEA State” means a State which is a contracting party to the EEA Agreement;

“general medical practitioner” has the same meaning as in the Health and Personal Social Services (General Medical Services Contracts) Regulations (Northern Ireland) 2004(5);

“patient” has the same meaning as in the Health and Personal Social Services (General Medical Services Contracts) Regulations (Northern Ireland) 2004;

“residential care home” and “nursing home” have the same meaning as in the Health and Personal Social Services (Quality, Improvement and Regulation) (Northern Ireland) Order 2003(6).

ClobazamAny patientTreatment of epilepsy
Cyanocobalamin TabletsA patient who is a vegan or who has a proven vitamin Bl2 deficiency of dietary origin

Treatment or prevention of vitamin B12 deficiency

Niferex Elixir 30ml

Paediatric Dropper Bottle

Infants born prematurely

Prophylaxis and treatment of iron deficiency

Nizoral CreamAny patient

Treatment of seborrhoeic dermatitis and pityriasis versicolor

The following drugs for the treatment of erectile dysfunction –

  • Alprostadil (Caverject), (MUSE), (Viridal)

  • Apomorphine

  • Hydrochloride (Uprima)

  • Moxisylyte

  • Hydrochloride (Erecnos)

  • Sildenafil (Viagra)

  • Tadalafil (Cialis)

  • Thymoxamine

  • Hydrochloride (Erecnos)

  • Vardenafil (Levitra)

(a)

Any man with erectile dysfunction who on 14th September 1998 was receiving a course of treatment under the Order, the National Health Service Act 1977(1), or the National Health Service (Scotland) Act 1978(2) for this condition with any of the following drugs –

  • Alprostadil (Caverject), (Muse), (Viridial)

  • Apmorphine hydrochloride (Uprima)

  • Moxisylyte Hydrochloride (Uprima)

  • Moxisylyte Hydrochloride (Erencos)

  • Sildenafil (Viagra)

  • Tadalafil (Cialis) Thymoxamine

  • Hydrochloride (Erecnos) Vardenafil (Levitra); or

(b)

a man who is a national of an EEA State who is entitled to treatment by virtue of Article 7(2) of Council Regulation 1612/68(3) as extended by the EEA Agreement or by virtue of any other enforceable Community right who has erectile dysfunction and was on 14th September 1998 receiving a course of treatment under a national health insurance system of an EEA State for this condition with any of the drugs listed in sub-paragraph (a); or

(c)

a man who is not a national of an EEA State but who is the member of the family of such a national who has an enforceable Community right to be treated no less favourably than the national in the provision of medical treatment and has erectile dysfunction and was being treated for that condition on 14th September 1998 with any of the drugs listed in sub-paragraph (a); or

(d)

a man who is suffering from any of the following –diabetes, multiple sclerosis, Parkinson’s disease, poliomyelitis, prostate cancer, severe pelvic injury, single gene neurological disease, spina bifida, spinal cord injury; or

(e)

a man who is receiving treatment for renal failure by dialysis; or

(f)

a man who has had the following surgery–prostatectomy; radical pelvic surgery; renal failure treated by transplant;

Treatment of erectile

dysfunction

Oseltamivir (Tamiflu)
(1)

A patient who is aged 1 year or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications from influenza where—

(a)

the Department has notified general medical practitioners that the influenza virus is circulating in the community(4);

(b)

the patient has an influenza-like illness; and

(c)

the patient can start therapy within 48 hours of the onset of symptoms.

(2)

Any patient suffering from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Department or are part the Regional Board’s antivirals distribution service.

Treatment of influenza
(3)

A patient who is aged 1 year or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, where—

(a)

the Department has notified general medical practitioners that the influenza virus is circulating in the community;

(b)

the patient has been exposed to an influenza-like illness through being in close contact with someone with whom he lives who is or has been suffering from an influenza-like illness;

(c)

the patient is not effectively protected by vaccination against influenza because —

(i)

he has not been vaccinated because vaccination is contraindicated;

(ii)

he has not been vaccinated since the previous influenza season;

(iii)

he has been vaccinated but it has yet to take effect; or

(iv)

he has been vaccinated but the vaccine is not well matched to the strain of influenza circulating in the locality in which the patient resides or is or has been present;

(d)

the patient lives in a residential care establishment and another resident or member of staff of the establishment has an influenza-like illness; and

(e)

the patient can start prophylaxis within 48 hours of exposure to an influenza-like illness.

(4)

Any patient at risk from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Department or are part the Regional Board’s antivirals distribution service.

Prophylaxis of influenza
Zanamivir (Relenza)
(1)

A patient who is aged 5 years or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications from influenza where—

(a)

the Department has notified general medical practitioners that the influenza virus is circulating in the community;

(b)

the patient has an influenza-like illness; and

(c)

in the case of a patient—

(i)

who has attained the age of 5 years but not the age of 13 years, that patient can start therapy within 36 hours of the onset of symptoms; and

(ii)

who is aged 13 years or over, that patient can start therapy within 48 hours of the onset of symptoms.

Treatment of influenza
(2)

Any patient at risk of or suffering from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Department or are part the Regional Board’s antivirals distribution service.

Prophylaxis or treatment of influenza.
(3)

O.J. No. L257, 19.10.68. p. 22 (O.J./S.E. 1968 (II) p. 475)

(4)

Notification is given by the Department of Health, Social Services and Public Safety via a letter from the Chief Medical Officer to general practitioners and other health professionals in or connected to the Health Service. In addition the notification is placed on the DHSSPS website which is www.dhsspsni.gov.uk

(5)

S.R. 2004 No. 140 to which there are amendments not relevant to these Regulations

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As Enacted or Made):The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

Explanatory Memorandum

Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Rule and provides information about its policy objective and policy implications. They aim to make the Statutory Rule accessible to readers who are not legally qualified and accompany any Northern Ireland Statutory Rule or Draft Northern Ireland Statutory Rule laid before the UK Parliament during the suspension of the Northern Ireland Assembly.

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as enacted version that was used for the print copy
  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as made version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources